1163 related articles for article (PubMed ID: 7936862)
21. Comparative evaluation of two combined measles-mumps-rubella vaccines based on AIK and Edmonston- Zagreb strains of measles virus.
Mirchamsy H; Nilforoushan MA; Shafyi A; Razavi J; Ashtiani MP; Youssofi I; Sassani A; Fateh G; Nassiri S
Kitasato Arch Exp Med; 1991 Sep; 64(2-3):141-7. PubMed ID: 1811112
[TBL] [Abstract][Full Text] [Related]
22. Effect of simultaneous administration of live measles vaccine on the "take rate" of live mumps vaccine.
André FE; Peetermans J
Dev Biol Stand; 1986; 65():101-7. PubMed ID: 3556770
[TBL] [Abstract][Full Text] [Related]
23. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
[TBL] [Abstract][Full Text] [Related]
24. Measles, mumps, rubella antibody surveillance: pilot study in Grampian, Scotland.
Narayan KM; Moffat MA
Health Bull (Edinb); 1992 Jan; 50(1):47-53. PubMed ID: 1612895
[TBL] [Abstract][Full Text] [Related]
25. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
[TBL] [Abstract][Full Text] [Related]
26. Decreased measles antibody response after measles-mumps-rubella vaccine in infants with colds.
Krober MS; Stracener CE; Bass JW
JAMA; 1991 Apr; 265(16):2095-6. PubMed ID: 2013930
[TBL] [Abstract][Full Text] [Related]
27. Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children.
Kanesaki T; Baba K; Tsuda N; Yabuuchi H; Yamanishi K; Takahashi M
Biken J; 1986 Dec; 29(3-4):63-71. PubMed ID: 3304276
[TBL] [Abstract][Full Text] [Related]
28. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.
Durando P; Esposito S; Bona G; Cuccia M; Desole MG; Ferrera G; Gabutti G; Pellegrino A; Salvini F; Henry O; Povey M; Marchetti F
Vaccine; 2016 Aug; 34(36):4278-84. PubMed ID: 27423382
[TBL] [Abstract][Full Text] [Related]
29. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group.
Reuman PD; Sawyer MH; Kuter BJ; Matthews H
Pediatr Infect Dis J; 1997 Jul; 16(7):662-7. PubMed ID: 9239770
[TBL] [Abstract][Full Text] [Related]
31. [Epidemiological analysis of immunity against vaccine-preventable diseases: rubella, measles, mumps and chickenpox].
Buxbaum S; Doerr HW; Allwinn R
Dtsch Med Wochenschr; 2001 Nov; 126(46):1289-93. PubMed ID: 11709730
[TBL] [Abstract][Full Text] [Related]
32. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
[TBL] [Abstract][Full Text] [Related]
33. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
[TBL] [Abstract][Full Text] [Related]
34. [Responses to triple viral and tetanus vaccination in HIV-infected children].
Echeverría Lecuona J; Aldamiz-Echevarría Azuara L; Cilla Eguiluz G; Pérez Trallero E
An Esp Pediatr; 1996 Apr; 44(4):317-20. PubMed ID: 8849078
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
Goh P; Lim FS; Han HH; Willems P
Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
[TBL] [Abstract][Full Text] [Related]
36. [Clinico-immunologic evaluation of a trivalent vaccine against measles, rubella and mumps].
Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
Minerva Pediatr; 1989 Mar; 41(3):117-22. PubMed ID: 2747598
[TBL] [Abstract][Full Text] [Related]
37. [The development and duration of immunity in children vaccinated against measles with the Edmonston-Zagreb vaccine].
Borcić B; Smerdel S; Abu Eldan J; Kolić J; Ferdebar M; Kordić D; Mohacek N
Lijec Vjesn; 1989; 111(4-5):131-4. PubMed ID: 2770398
[TBL] [Abstract][Full Text] [Related]
38. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
[TBL] [Abstract][Full Text] [Related]
39. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
Shinefield HR; Black S; Kuter BJ
J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
[TBL] [Abstract][Full Text] [Related]
40. Measles, mumps and rubella immunisation in children at risk of infection with human immunodeficiency virus.
Molyneaux PJ; Mok JY; Burns SM; Yap PL
J Infect; 1993 Nov; 27(3):251-3. PubMed ID: 8308316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
